<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121080</url>
  </required_header>
  <id_info>
    <org_study_id>R2222-HV-1326</org_study_id>
    <nct_id>NCT02121080</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety,
      tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in
      cohorts of healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of treatment-emergent adverse events (TEAEs) in participants treated with REGN2222 or placebo.</measure>
    <time_frame>from day 1 up to week 20 (EOS)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>from day 1 over time up to week 20</time_frame>
    <description>Serum concentration of REGN2222 over time up to week 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of antibodies</measure>
    <time_frame>from day 1 over time up to week 20</time_frame>
    <description>The presence or absence of antibodies against REGN2222 over time up to week 20</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2222(SAR438584)</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy man or woman aged 18 to 60 years

          2. Body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive

          3. Willing and able to comply with clinic visits and study-related procedures

          4. Provide signed informed consent

        Exclusion Criteria:

          1. Serum hemoglobin, creatinine, alkaline phosphatase, CPK, and/or hepatic enzymes
             (aspartate aminotransferase [AST] and alanine aminotransferase [ALT], total bilirubin
             [unless the investigator has evidence that increased bilirubin corresponds to a
             Gilbert's type syndrome with elevated indirect bilirubin]) that is &gt;1.5 the upper
             limit of normal (ULN), or any laboratory findings showing evidence of organ
             dysfunction or any clinically significant abnormalities from the normal range, as
             determined by the investigator at the screening visit

          2. Use of any concomitant medications within 30 days or at least 5 half-lives, whichever
             is longer, of the screening visit, including prescription medications (except
             contraceptives), nutritional supplements, and over-the-counter medications (except
             acetaminophen)

          3. Hospitalization for any reason within 60 days of the screening visit

          4. History of or positive human immunodeficiency virus (HIV) screen result at the
             screening visit

          5. History of or positive blood test result for hepatitis B surface antigen and/or
             hepatitis C virus antibody at the screening visit

          6. History of autoimmune disease

          7. History of respiratory disease (e.g, asthma, chronic obstructive pulmonary disease)

          8. History of drug or alcohol abuse within 1 year prior to the screening visit

          9. Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days, or within at least 5 half-lives, of the investigational
             drug (whichever is longer) prior to the screening visit

         10. Pregnant or breastfeeding woman

         11. Sexually active men* or women of childbearing potential** who are unwilling to
             practice adequate contraception during the study, and up to 3 months after the last
             dose of the study drug (adequate contraceptive measures include stable use of oral
             contraceptives or other prescription pharmaceutical contraceptives for 2 or more
             menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation;
             vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus
             contraceptive sponge, foam, or jelly)

               -  Contraception is not required for men with documented vasectomy. **Postmenopausal
                  women must be amenorrheic for at least 12 months in order not to be considered of
                  childbearing potential. Contraception is not required for women with documented
                  hysterectomy or tubal ligation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

